Search Results

329 articles with title/keywords/abstract containing Cost-allocation

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
modify search
Display per page 

Increase in pharmaceutical budget receives warm welcome in NZ

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 584, 2009-08-08 , pp. 10-10(1)

Publisher: Adis International

Aid money wasted on privatising healthcare in poor countries

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 573, 2009-03-07 , pp. 2-2(1)

Publisher: Adis International

Time for NICE to get nasty, says UK health economist

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 570, 2009-01-24 , pp. 2-2(1)

Publisher: Adis International

UK NHS holds surplus, but tough times ahead

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 569, 2009-01-10 , pp. 1-1(1)

Publisher: Adis International

An additional $US275 million in funding for the US FDA will not be available until March or April 2009

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 560, 2008-08-23 , pp. 10-10(1)

Publisher: Adis International

HIV drugs made cheaper, accessible to more patients

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 559, 2008-08-09 , pp. 14-14(1)

Publisher: Adis International

UK govt boosts funding to fight health inequalities

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 556, 2008-06-28 , pp. 9-9(1)

Publisher: Adis International

€281.5 million is being invested by the Spanish ministry of health to make sure that day-to-day research is carried out in hospitals

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 553, 2008-05-17 , pp. 10-10(1)

Publisher: Adis International

A fund to combat neglected tropical diseases should be established by developed countries

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 553, 2008-05-17 , pp. 11-11(1)

Publisher: Adis International

Malaria drug price cut to improve access.

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 552, 2008-05-03 , pp. 10-10(1)

Publisher: Adis International

The UK pharma industry has little confidence in the current market environment −

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 550, 2008-04-05 , pp. 11-11(1)

Publisher: Adis International

Proposed changes to Japan's pharmaceutical pricing mechanism for 2008 and beyond are "modest"

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 548, 2008-03-08 , pp. 10-10(1)

Publisher: Adis International

A recent report to the German government is being hailed as a significant revision to drug policy.

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 548, 2008-03-08 , pp. 10-10(1)

Publisher: Adis International

China ups healthcare spending to benefit poor

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 549, 2008-03-22 , pp. 11-11(1)

Publisher: Adis International

Cipla's recent price cut of 5−15% for three of its antiretrovirals is "nowhere near enough" to make such drugs affordable and accessible to all Indians in need

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 544, 2008-01-12 , pp. 11-11(1)

Publisher: Adis International

The US HHS has announced that the government will no longer pay for US immigrants' chemotherapy under Medicaid

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 543, 2007-12-15 , pp. 11-11(1)

Publisher: Adis International

Migraine research vastly underfunded

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 539, 2007-10-20 , pp. 4-4(1)

Publisher: Adis International

Merck has been criticised by the AHF over the announced price for its key new HIV/AIDS drug, raltegravir [Isentress].

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 539, 2007-10-20 , pp. 11-11(1)

Publisher: Adis International

UK NHS funding injection fails to pay off

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 537, 2007-09-22 , pp. 11-11(1)

Publisher: Adis International

Merck has offered to reduce the price of efavirenz in Thailand, but with the condition that the country revokes its compulsory license for the drug.

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 530, 2007-06-16 , pp. 11-11(1)

Publisher: Adis International

modify search
Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A